65 related articles for article (PubMed ID: 35700670)
1. Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies.
Masanneck L; Rolfes L; Regner-Nelke L; Willison A; Räuber S; Steffen F; Bittner S; Zipp F; Albrecht P; Ruck T; Hartung HP; Meuth SG; Pawlitzki M
Mult Scler Relat Disord; 2022 Jul; 63():103927. PubMed ID: 35700670
[TBL] [Abstract][Full Text] [Related]
2. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
[TBL] [Abstract][Full Text] [Related]
3. Risk of secondary progressive multiple sclerosis after early worsening of disability.
Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
[TBL] [Abstract][Full Text] [Related]
4. Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.
Müller J; Cagol A; Lorscheider J; Tsagkas C; Benkert P; Yaldizli Ö; Kuhle J; Derfuss T; Sormani MP; Thompson A; Granziera C; Kappos L
JAMA Neurol; 2023 Nov; 80(11):1232-1245. PubMed ID: 37782515
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
[TBL] [Abstract][Full Text] [Related]
6. Multiple Sclerosis Progression and Relapse Activity in Children.
Iaffaldano P; Portaccio E; Lucisano G; Simone M; Manni A; Guerra T; Paolicelli D; Betti M; De Meo E; Pastò L; Razzolini L; Rocca MA; Ferrè L; Brescia Morra V; Patti F; Zaffaroni M; Gasperini C; De Luca G; Ferraro D; Granella F; Pozzilli C; Romano S; Gallo P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Banfi P; Lugaresi A; Totaro R; Spitaleri D; Cocco E; Di Palma F; Maimone D; Valentino P; Torri Clerici V; Protti A; Maniscalco GT; Salemi G; Pesci I; Aguglia U; Lepore V; Filippi M; Trojano M; Amato MP;
JAMA Neurol; 2024 Jan; 81(1):50-58. PubMed ID: 38010712
[TBL] [Abstract][Full Text] [Related]
7. Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis.
Gosetti di Sturmeck T; Malimpensa L; Ferrazzano G; Belvisi D; Leodori G; Lembo F; Brandi R; Pascale E; Cattaneo A; Salvetti M; Conte A; D'Onofrio M; Arisi I
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928049
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis.
Abdelhak A; Benkert P; Schaedelin S; Boscardin WJ; Cordano C; Oechtering J; Ananth K; Granziera C; Melie-Garcia L; Montes SC; Beaudry-Richard A; Achtnichts L; Oertel FC; Lalive PH; Leppert D; Müller S; Henry RG; Pot C; Matthias A; Salmen A; Oksenberg JR; Disanto G; Zecca C; D'Souza M; Du Pasquier R; Bridel C; Gobbi C; Kappos L; Hauser SL; Cree BAC; Kuhle J; Green AJ;
JAMA Neurol; 2023 Dec; 80(12):1317-1325. PubMed ID: 37930670
[TBL] [Abstract][Full Text] [Related]
9. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
Kızılay T; Akbayir E; Erol R; Demir AS; Özkan Yaşargün D; Yilmaz V; Tuzun E; Turkoglu R
Eur Neurol; 2024 Jun; ():1-8. PubMed ID: 38754397
[TBL] [Abstract][Full Text] [Related]
10. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
Cagol A; Benkert P; Melie-Garcia L; Schaedelin SA; Leber S; Tsagkas C; Barakovic M; Galbusera R; Lu PJ; Weigel M; Ruberte E; Radue EW; Yaldizli Ö; Oechtering J; Lorscheider J; D'Souza M; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier RA; Lalive PH; Pravatà E; Weber J; Cattin PC; Absinta M; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
Neurology; 2024 Jan; 102(1):e207768. PubMed ID: 38165377
[TBL] [Abstract][Full Text] [Related]
11. Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
Rotstein D; Solomon JM; Sormani MP; Montalban X; Ye XY; Dababneh D; Muccilli A; Shah P
Neurology; 2022 Jul; 99(2):e209-e220. PubMed ID: 35473761
[TBL] [Abstract][Full Text] [Related]
12. Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
Rosenstein I; Nordin A; Sabir H; Malmeström C; Blennow K; Axelsson M; Novakova L
J Neurol; 2024 Apr; ():. PubMed ID: 38668889
[TBL] [Abstract][Full Text] [Related]
13. Progression Independent of Relapse Activity in Multiple Sclerosis: Closer to Solving the Pathologic Puzzle.
Tur C; Rocca MA
Neurology; 2024 Jan; 102(1):e207936. PubMed ID: 38165383
[TBL] [Abstract][Full Text] [Related]
14. Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Koch MW; Moral E; Brieva L; Mostert J; Strijbis EM; Comtois J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Cutter G
Mult Scler; 2023 Dec; 29(14):1776-1785. PubMed ID: 37830451
[TBL] [Abstract][Full Text] [Related]
15. Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
Pfeuffer S; Wolff S; Aslan D; Rolfes L; Korsen M; Pawlitzki M; Albrecht P; Havla J; Huttner HB; Kleinschnitz C; Meuth SG; Pul R; Ruck T
Neurology; 2024 Jul; 103(2):e209574. PubMed ID: 38870471
[TBL] [Abstract][Full Text] [Related]
16. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP;
J Neurol; 2024 May; ():. PubMed ID: 38805052
[TBL] [Abstract][Full Text] [Related]
17. Identification and management of subclinical disease activity in early multiple sclerosis: a review.
Ontaneda D; Chitnis T; Rammohan K; Obeidat AZ
J Neurol; 2024 Apr; 271(4):1497-1514. PubMed ID: 37864717
[TBL] [Abstract][Full Text] [Related]
18. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
Newsome SD; Binns C; Kaunzner UW; Morgan S; Halper J
Neurol Ther; 2023 Dec; 12(6):1909-1935. PubMed ID: 37819598
[TBL] [Abstract][Full Text] [Related]
19. Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
Maarouf A; Stellmann JP; Rico A; Boutiere C; Demortiere S; Durozard P; Zaaraoui W; Ranjeva JP; Pelletier J; Audoin B
J Neurol Neurosurg Psychiatry; 2024 May; ():. PubMed ID: 38719433
[TBL] [Abstract][Full Text] [Related]
20. High frequency of circulating non-classical monocytes is associated with stable remission in relapsing-remitting multiple sclerosis.
Minote M; Sato W; Kimura K; Kimura A; Lin Y; Okamoto T; Takahashi R; Yamamura T
Immunol Med; 2024 Mar; ():1-15. PubMed ID: 38539051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
